|
In € millions, except earnings per share and dividend (in €) |
2016 |
2017 |
2018 |
2019 |
2020 |
|
Order intake |
16,514 |
14,920 |
16,034 |
19,142 |
18,476 |
|
Order book at end of period |
33,530 |
31,914 |
32,329 |
33,839 |
34,430 |
|
Sales |
14,885 |
15,795 |
15,855 |
18,401 |
16,989 |
|
Total change |
+ 5.8% |
+ 6.1% |
+4.1% |
+16.1% |
-7.7% |
|
Organic change |
+ 6.8% |
+ 7.2% |
+5.3% |
+0.8% |
-10.4% |
|
EBIT (1) |
1,354 |
1,543 |
1,685 |
2,008 |
1,352 |
|
In % of sales |
9.1% |
9.8% |
10.6% |
10.9% |
8.0% |
|
Adjusted net income , Group share (1) |
897 |
982 |
1,178 |
1,405 |
937 |
|
Consolidated net income, Group share |
946 |
822 |
982 |
1,122 |
483 |
|
Adjusted net income Group share, per share (EPS)(1) |
4.25 |
4.64 |
5.55 |
6.61 |
4.40 |
|
Dividend per share |
1.60 |
1.75 |
2.08 |
0.60(2) |
1.76(3) |
|
Free operating cash-flow (1) |
954 |
1,365 |
811 |
1,372 |
1057 |
|
Net cash position (debt) at end of period |
2,366 |
2,971 |
3,181 |
-3,311 |
-2,549 |
|
Self-funded R&D |
731 |
797 |
879 |
1,097 |
1,025 |
|
Consolidated headcount at year-end |
64,071 |
64,860 |
66,135 |
82,605 |
80,702 |
- (1) Non-GAAP measures. See definitions in the corresponding reference documents.
- (2) Amount adjusted down in the context of the Covid-19 crisis. Initial amount: €2.65